Learn how our own immune system cells can be engineered to fight some cancers.
Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option.
On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).
The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.
Although commonly associated with high-grade myelodysplastic syndrome (MDS) and MDS with a complex karyotype, TP53 mutations also occur in low-grade MDS and MDS with a non-complex karyotype. In latter cases, their clinicopathological features and the characteristics of TP53 mutations remain poorly characterized.
176 MDS cases with TP53 mutations were stratified and characterized based on their karyotype and histologic subtype.
Patients with lower-risk
Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to